Department of Neuroscience, Neurology Division, Annunziata Hospital, Cosenza, Italy.
Clin Drug Investig. 2013 Feb;33(2):151-4. doi: 10.1007/s40261-012-0051-z.
Dysaesthetic pain is a common neuropathic pain in patients with multiple sclerosis. Both tricyclic antidepressants (i.e., amitriptyline and duloxetine) and antiepileptic drugs (i.e., carbamazepine, gabapentin and pregabalin) represent first-line treatment of neuropathic pain. However, topiramate, an antiepileptic drug, also demonstrated clinical efficacy in these patients. In this report we describe the case of a 42-year-old woman with an 8-year history of multiple sclerosis who developed dysaesthetic pain in the lower limbs, and was successfully treated with topiramate at a final dose of 150 mg/day. About 8 months after beginning topiramate treatment, the patient had not shown any dysaesthetic pain, and no adverse events related to topiramate had been recorded.
感觉异常性疼痛是多发性硬化症患者常见的神经病理性疼痛。三环类抗抑郁药（如阿米替林和度洛西汀）和抗癫痫药（如卡马西平、加巴喷丁和普瑞巴林）均为治疗神经病理性疼痛的一线药物。然而，抗癫痫药托吡酯在这些患者中也表现出了临床疗效。在本报告中，我们描述了一位 42 岁女性患者的病例，她患有多发性硬化症 8 年，下肢出现感觉异常性疼痛，服用托吡酯（最终剂量为 150 mg/天）治疗后症状得到了成功缓解。开始服用托吡酯治疗大约 8 个月后，患者未再出现感觉异常性疼痛，且未记录到与托吡酯相关的任何不良事件。
